Bovie Medical Announces J-Plasma® Sales Channel Partnership with Arteriocyte Medical Systems
June 30 2016 - 5:10PM
Business Wire
- Provides immediate access to plastic
surgery market via specialist sales force channel
- Complementary to existing sales
efforts while broadening the adoption of J-Plasma® by office-based
surgeons
Bovie Medical Corporation (NYSEMKT:BVX), a maker of
medical devices and supplies and the developer of J-Plasma®, a
patented new surgical product, today announced it had entered into
a sales channel partnership Agreement with Arteriocyte Medical
Systems, Inc., to sell J-Plasma® to its network of plastic
surgeons.
The Agreement will put Bovie’s innovative J-Plasma® product in
the hands of Arteriocyte’s U.S. sales network, significantly
expanding its potential for use in office-based practices.
Arteriocyte’s sales team has expertise in both biologics, and
medical devices utilized in the plastic surgery category of care,
and a portfolio of novel products that are complementary to
J-Plasma®.
“We are delighted to sign this Agreement with Arteriocyte, a
company with an exemplary reputation in selling innovative cellular
therapy based medical devices,” said Robert L. Gershon, Chief
Executive Officer. “J-Plasma®’s precision and lack of thermal
spread make it a natural fit for the plastic surgeon, and
Arteriocyte’s nationwide reach and complementary product portfolio
will significantly raise awareness of the technology, and
complement our existing sales efforts. This partnership is an
important milestone in our strategy to scale J-Plasma® across
multiple specialties, leveraging the different applications for
this unique surgical technology.”
Arteriocyte Medical Systems is a medical device company
dedicated to developing solutions to help patients heal
faster. Collaborations and partnerships are core to its
approach in seeking innovations and technologies that target unmet
medical needs.
“J-Plasma’s potential to substantially reduce patient down-time
aligns well with our strategic priorities, and we look forward to
successfully launching this new product to our network of plastic
surgeons nationwide,” said Donald Brown, Chief Executive Officer of
Arteriocyte.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma®, a patented new
plasma-based surgical product for cutting and coagulation.
J-Plasma® utilizes a helium ionization process to produce a stable,
focused beam of ionized gas that provides surgeons with greater
precision, minimal invasiveness and an absence of conductive
currents through the patient during surgery. Bovie Medical
Corporation is also a leader in the manufacture of a range of
electrosurgical products and technologies, marketed through both
private labels and the Company’s own well-respected brands (Bovie®,
Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company’s current and new products,
please refer to the Investor Relations section of Bovie Medical
Corporation’s www.boviemed.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160630006368/en/
Investor Relations:MBS Value PartnersHugh Collins,
212-223-4632investor.relations@boviemed.com
Bovie (AMEX:BVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bovie (AMEX:BVX)
Historical Stock Chart
From Apr 2023 to Apr 2024